Less Ads, More Data, More Tools Register for FREE

Pin to quick picksWise Group Regulatory News (WISE)

Share Price Information for Wise Group (WISE)

Share Price is delayed by 15 minutes
Get Live Data
826.00    0.00 (0.00%)
Bid:
820.00
Ask:
826.00
Spread: 6.00 (0.732%)
Market Cap: £8.26b
WISE Live PriceLast checked at - London Stock Exchange

Intraday Wise Group Share Chart

Half-year Report

29 Nov 2021 13:24

RNS Number : 9136T
Wise PLC
29 November 2021
 

Wise plc

29 November 2021

 

Release of unaudited historic financial information

 

Wise is today releasing selected historic consolidated financial statements on an unaudited half yearly basis for the year ended 31 March 2021.

 

 

Enquiries

Martin Adams - Head of Owner Relations

martin.adams@wise.com

 

 

Condensed consolidated statement of comprehensive income (unaudited)

 

 

 

Year ended

Half-year ended

Half-year ended

 

31 March 2021

30 September 2020

31 March 2021

 

 

 

 

Revenue

421.0

192.2

228.8

Cost of sales

(151.7)

(71.8)

(79.9)

Net credit losses on financial assets

(8.8)

(1.2)

(7.6)

Gross profit

260.5

119.2

141.3

 

 

 

 

Administrative expenses

(217.5)

(97.6)

(119.9)

Interest income from investments and operating assets

1.9

1.0

0.9

Interest expense from operating assets

(3.8)

(1.6)

(2.2)

Other income

3.8

1.1

2.7

Operating profit

44.9

22.1

22.8

 

 

 

 

Finance expense

(3.8)

(2.1)

(1.7)

Profit before tax

41.1

20.0

21.1

 

 

 

 

Income tax expense

(10.2)

(5.4)

(4.8)

Profit for the period

30.9

14.6

16.3

 

 

 

 

Other comprehensive income

 

 

 

Items that may be reclassified to profit or loss:

 

 

 

Fair value (loss)/gain on investments

(3.0)

0.2

(3.2)

Currency translation differences

(3.8)

0.3

(4.1)

Total other comprehensive (loss)/income

(6.8)

0.5

(7.3)

 

 

 

 

Total comprehensive income for the period

24.1

15.1

9.0

 

 

 

 

Condensed consolidated statement of financial position (unaudited)

 

 

 

As at 31 March

As at 30 September

As at 31 March

 

 

2020

2020

2021

Non-current assets

 

 

 

Deferred tax assets

32.0

38.7

56.7

Property, plant and equipment

19.1

16.7

24.0

Intangible assets

21.3

24.4

27.5

Trade and other receivables

7.6

8.3

15.1

Total non-current assets

80.0

88.1

123.3

 

 

 

 

Current assets

 

 

 

Current tax assets

2.1

1.7

1.1

Trade and other receivables

102.6

89.2

81.3

Short-term financial investments

114.1

289.3

737.5

Cash and cash equivalents

2,077.6

2,872.1

3,358.6

Total current assets

2,296.4

3,252.3

4,178.5

 

 

 

 

Total assets

2,376.4

3,340.4

4,301.8

 

 

 

 

Non-current liabilities

 

 

 

Deferred tax liabilities

-

-

2.0

Non-current borrowings

59.6

9.0

95.2

Non-current trade and other payables

7.4

9.5

22.6

Total non-current liabilities

67.0

18.5

119.8

 

 

 

 

Current liabilities

 

 

 

Borrowings

4.2

28.3

3.5

Current tax liabilities

0.7

0.8

2.0

Trade and other payables

2,107.7

3,051.2

3,891.2

Total current liabilities

2,112.6

3,080.3

3,896.7

 

 

 

 

Total liabilities

2,179.6

3,098.8

4,016.5

 

 

 

 

Equity

 

 

 

Share capital

9.4

9.4

9.4

Equity merger reserve

111.1

112.0

(8.0)

Share-based payment reserves

63.8

90.0

124.5

Own shares reserve

-

-

-

Other reserves

2.3

2.5

(0.7)

Retained earnings

8.9

26.1

162.6

Currency translation differences

1.3

1.6

(2.5)

Total equity

196.8

241.6

285.3

 

 

 

 

Total liabilities and equity

2,376.4

3,340.4

4,301.8

 

 

 

Condensed consolidated statement of cash flows (unaudited)

 

 

 

 

Year ended

Half-year ended

Half-year ended

 

31 March 2021

30 September 2020

31 March 2021

Cash flows from operating activities

 

 

 

 

 

 

 

Cash generated from operations

2,076.3

1,012.0

1,064.3

Interest received

7.6

2.7

4.9

Interest expense paid

(6.0)

(2.7)

(3.3)

Corporate income tax paid

(4.0)

(0.8)

(3.2)

Net cash generated from operating activities

2,073.9

1,011.2

1,062.7

 

 

 

 

Cash flows from investing activities

 

 

 

 

 

 

 

Payments for property, plant and equipment

(2.3)

(1.1)

(1.2)

Payment for intangible assets

(20.9)

(10.1)

(10.8)

Payments for financial assets at FVOCI

(723.9)

(222.7)

(501.2)

Proceeds from sale and maturity of financial assets at FVOCI

75.3

41.1

34.2

Net cash used in investing activities

(671.8)

(192.8)

(479.0)

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

 

Proceeds from issues of shares and other equity

0.9

0.9

-

Proceeds from borrowings

118.6

25.0

93.6

Repayments of borrowings

(90.0)

(50.0)

(40.0)

Payments for lease liabilities

(4.7)

(2.4)

(2.3)

Net cash generated from financing activities

24.8

(26.5)

51.3

 

 

 

 

Net increase in cash and cash equivalents

1,426.9

791.9

635.0

 

 

 

 

Cash and cash equivalents at beginning of the period

2,077.6

2,077.6

2,872.1

Effects of exchange rate changes on cash and cash equivalents

(145.9)

2.6

(148.5)

Cash and cash equivalents at end of the period

3,358.6

2,872.1

3,358.6

 

 

Condensed consolidated statement of changes in equity (unaudited)

 

 

 

Share capital

Equity merger reserve

Share-based payment reserves

Own shares reserve

Other reserves

Retained earnings

Currency translation differences

Total equity

 
 
 

 

 

 

 

 

 

 

 

 

 

At 1 April 2020

9.4

111.1

63.8

-

2.3

8.9

1.3

196.8

 

 

 

 

 

 

 

 

 

 

 

Profit for the period

-

-

-

-

-

14.6

-

14.6

 

Fair value gain on investments

-

-

-

-

0.2

-

-

0.2

 

Foreign currency translation differences

-

-

-

-

-

-

0.3

0.3

 

Total comprehensive income for the period

-

-

-

-

0.2

14.6

0.3

15.1

 

 

 

 

 

 

 

 

 

 

 

Share-based employee compensation expense

-

-

18.0

-

-

-

-

18.0

 

Deferred tax on share-based compensation

-

-

10.8

-

-

-

-

10.8

 

Share options exercises

-

0.9

(2.6)

-

-

2.6

-

0.9

 

At 30 September 2020

9.4

112.0

90.0

-

2.5

26.1

1.6

241.6

 

 

 

 

 

 

 

 

 

 

 

Profit for the period

-

-

-

-

-

16.3

-

16.3

 

Fair value loss on investments

-

-

-

-

(3.2)

-

-

(3.2)

 

Foreign currency translation differences

-

-

-

-

-

-

(4.1)

(4.1)

 

Total comprehensive income for the period

-

-

-

-

(3.2)

16.3

(4.1)

9.0

 

 

 

 

 

 

 

 

 

 

 

Reduction of share capital

-

(120.0)

-

-

-

120.0

-

-

 

Share-based employee compensation expense

-

-

18.9

-

-

-

-

18.9

 

Deferred tax on share-based compensation

-

-

15.8

-

-

-

-

15.8

 

Share options exercises

-

-

(0.2)

-

-

0.2

-

-

 

At 31 March 2021

9.4

(8.0)

124.5

-

(0.7)

162.6

(2.5)

285.3

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IR FLFFVLFLAFIL
Date   Source Headline
3rd Jun 20264:25 pmRNSHolding(s) in Company
2nd Jun 202611:44 amRNSTotal Voting Rights
1st Jun 20268:59 amRNSWise Europe
11th May 202611:00 amRNSWise debuts US listing on Nasdaq
11th May 20268:00 amRNSTotal Voting Rights
11th May 20268:00 amRNSCancellation - Wise plc
11th May 20267:00 amRNSScheme of Arrangement becomes effective
6th May 202612:43 pmRNSDirector/PDMR Shareholding
1st May 20261:55 pmRNSTotal Voting Rights
27th Apr 20263:33 pmRNSScheme of Arrangement
24th Apr 20261:07 pmRNSDirector/PDMR Shareholding
23rd Apr 20262:49 pmRNSTotal Voting Rights
22nd Apr 20263:13 pmRNSDirector/PDMR Shareholding
22nd Apr 20261:32 pmRNSHolding(s) in Company
16th Apr 20264:01 pmRNSDirector/PDMR Shareholding
13th Apr 20261:39 pmRNSPublication of a Prospectus
13th Apr 20267:53 amRNSQ4 FY2026 Trading Update
13th Apr 20267:01 amRNSTranslation of IFRS financials into US GAAP
13th Apr 20267:00 amRNSQ4 FY2026 Trading Update
9th Apr 20269:05 amRNSNotice of Q4 FY2026 Results
1st Apr 20262:50 pmRNSTotal Voting Rights
3rd Mar 202610:46 amRNSTotal Voting Rights
2nd Mar 20269:00 amRNSBoard Appointment
16th Feb 202610:43 amRNSChange of Adviser
4th Feb 202612:54 pmRNSHolding(s) in Company
2nd Feb 20264:13 pmRNSTotal Voting Rights
30th Jan 20263:43 pmRNSHolding(s) in Company
23rd Jan 202612:02 pmRNSDirector/PDMR Shareholding
20th Jan 20264:15 pmRNSDirector/PDMR Shareholding
20th Jan 20267:00 amRNSWise Q3 FY26 trading update
19th Jan 20263:12 pmRNSDirector/PDMR Shareholding
2nd Jan 20261:11 pmRNSTotal Voting Rights
3rd Dec 202512:53 pmRNSDirector/PDMR Shareholding
1st Dec 20252:57 pmRNSTotal Voting Rights
21st Nov 202512:35 pmRNSPublication of pricing supplements
18th Nov 20255:00 pmRNSDirector/PDMR Shareholding
13th Nov 20259:14 amRNSEstablishment of Euro Medium Term Note Programme
10th Nov 202510:28 amRNSDirector/PDMR Shareholding
7th Nov 20253:24 pmRNSDirector/PDMR Shareholding
6th Nov 20257:00 amRNSFY26 Half Year Results
3rd Nov 20254:35 pmRNSTotal Voting Rights
16th Oct 20255:20 pmRNSDirector/PDMR Shareholding
10th Oct 20251:46 pmRNSTotal Voting Rights
9th Oct 20252:52 pmRNSDirector/PDMR Shareholding
3rd Oct 20253:36 pmRNSDirector/PDMR Shareholding
25th Sep 20253:31 pmRNSResult of AGM
23rd Sep 20253:40 pmRNSHolding(s) in Company
23rd Sep 20252:03 pmRNSTotal Voting Rights
9th Sep 20255:56 pmRNSDirector/PDMR Shareholding
1st Sep 20252:13 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.